Traitements systémiques émergents de la dermatite atopique [Emerging systemic treatments of atopic dermatitis]

Détails

ID Serval
serval:BIB_96EE1E2181A8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Traitements systémiques émergents de la dermatite atopique [Emerging systemic treatments of atopic dermatitis]
Périodique
Revue medicale suisse
Auteur(s)
Di Lucca-Chrisment J., Gilliet M.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
28/03/2018
Peer-reviewed
Oui
Volume
14
Numéro
600
Pages
685-689
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Atopic dermatitis (AD) is the most common inflammatory dermatitis for which molecular research is currently extending. Mostly mediated by helper T lymphocytes type 2 (Th2), it seems that Th22 and Th17 can also be involved on a smaller scale. An IL-4/IL-13 inhibitor, key cytokines of the Th2 pathway, has recently been recognized as a new treatment for AD and has opened the field to multiple clinical trials for other selective immunosuppressants such as biologics and small molecules. These advances make us hope for the development of more effective and better-tolerated treatments than conventional immunosuppressants. In addition, they promise to advance the knowledge of this complex inflammatory pathology and its clinical subtypes.
Mots-clé
Cytokines/metabolism, Dermatitis, Atopic/drug therapy, Humans, Immunosuppressive Agents/therapeutic use, Th17 Cells
Pubmed
Création de la notice
29/03/2018 18:04
Dernière modification de la notice
20/08/2019 15:58
Données d'usage